Fennec Pharmaceuticals Inc. (TSX: FRX)
Canada
· Delayed Price · Currency is CAD 7.35
+0.76 (11.53%)
Nov 22, 2024, 3:47 PM EST
Fennec Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 49.35 | 21.25 | 1.54 | - | 0.17 | - | Upgrade
|
| Revenue Growth (YoY) | 278.09% | 1284.50% | - | - | - | - | Upgrade
|
| Cost of Revenue | 3.2 | 1.26 | 0.09 | - | - | - | Upgrade
|
| Gross Profit | 46.15 | 19.99 | 1.45 | - | 0.17 | - | Upgrade
|
| Selling, General & Admin | 44.18 | 32.71 | 20.51 | 12.24 | 12.95 | 7.4 | Upgrade
|
| Research & Development | 0.29 | 0.06 | 3.53 | 4.98 | 5.11 | 5.61 | Upgrade
|
| Operating Expenses | 44.46 | 32.76 | 24.04 | 17.22 | 18.06 | 13.01 | Upgrade
|
| Operating Income | 1.68 | -12.77 | -22.59 | -17.22 | -17.89 | -13.01 | Upgrade
|
| Interest Expense | -4.15 | -3.68 | -1.13 | -0.14 | -0.41 | -0.06 | Upgrade
|
| Interest & Investment Income | 1.4 | 0.44 | 0.2 | 0.05 | 0.09 | 0.32 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | 0.01 | -0.01 | -0.01 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -1.12 | -16.01 | -23.53 | -17.32 | -18.21 | -12.78 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.04 | -0.18 | -0.03 | 0.1 | - | Upgrade
|
| Pretax Income | -1.13 | -16.05 | -23.71 | -17.35 | -18.11 | -12.78 | Upgrade
|
| Net Income | -1.13 | -16.05 | -23.71 | -17.35 | -18.11 | -12.78 | Upgrade
|
| Net Income to Common | -1.13 | -16.05 | -23.71 | -17.35 | -18.11 | -12.78 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 26 | 26 | 24 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 27 | 26 | 26 | 24 | 20 | Upgrade
|
| Shares Change (YoY) | 2.34% | 1.14% | 1.03% | 9.71% | 19.14% | 5.04% | Upgrade
|
| EPS (Basic) | -0.04 | -0.60 | -0.90 | -0.67 | -0.76 | -0.64 | Upgrade
|
| EPS (Diluted) | -0.04 | -0.60 | -0.90 | -0.67 | -0.76 | -0.64 | Upgrade
|
| Free Cash Flow | 23.59 | -17.14 | -18.06 | -14.22 | -15.6 | -9.06 | Upgrade
|
| Free Cash Flow Per Share | 0.87 | -0.65 | -0.69 | -0.55 | -0.66 | -0.46 | Upgrade
|
| Gross Margin | 93.52% | 94.08% | 94.40% | - | 100.00% | - | Upgrade
|
| Operating Margin | 3.41% | -60.09% | -1471.60% | - | -10520.59% | - | Upgrade
|
| Profit Margin | -2.30% | -75.50% | -1544.89% | - | -10652.35% | - | Upgrade
|
| Free Cash Flow Margin | 47.81% | -80.67% | -1176.42% | - | -9173.53% | - | Upgrade
|
| EBIT | 1.68 | -12.77 | -22.59 | -17.22 | -17.89 | -13.01 | Upgrade
|
| EBIT Margin | 3.41% | -60.09% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.